Renalytix Plc
RENX.L · LSE
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Market Cap | £0 | £0 | £0 | £0 |
| - Cash | £0 | £0 | £0 | £0 |
| + Debt | £0 | £0 | £0 | £0 |
| Enterprise Value | £0 | £0 | £0 | £0 |
| Revenue | £0 | £0 | £0 | £0 |
| % Growth | 39.7% | -10.9% | 9.5% | – |
| Gross Profit | £0 | £0 | £0 | -£0 |
| % Margin | 54.6% | 19.2% | 6.1% | -12.3% |
| EBITDA | -£0 | -£0 | -£0 | -£0 |
| % Margin | -1,029.1% | -772.4% | -932.6% | -1,134% |
| Net Income | -£0 | -£0 | -£0 | -£0 |
| % Margin | -532.5% | -905.7% | -1,207.2% | -1,447.3% |
| EPS Diluted | -0.04 | -0.045 | -0.051 | -0.079 |
| % Growth | 10.7% | 12.7% | 35.4% | – |
| Operating Cash Flow | -£0 | -£0 | -£0 | -£0 |
| Capital Expenditures | £0 | £0 | -£0 | -£0 |
| Free Cash Flow | -£0 | -£0 | -£0 | -£0 |